Literature DB >> 21342185

Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells.

Christian Schütz1, Sabine Hoves, Dagmar Halbritter, Huang-Ge Zhang, John D Mountz, Martin Fleck.   

Abstract

Numerous studies have been performed in vitro and in various animal models to modulate the interaction of dendritic cells (DC) and T cells by Fas (CD95/Apo-1) signalling to delete activated T cells via induction of activation-induced cell death (AICD). Previously, we could demonstrate that Fas ligand (FasL/CD95L)-expressing 'killer-antigen-presenting cells' can be generated from human monocyte-derived mature DC (mDC) using adenoviral gene transfer. To evaluate whether these FasL-expressing mDC (mDC-FasL) could eliminate alloreactive primary human T cells in vitro, co-culture experiments were performed. Proliferation of human T cells was markedly reduced in primary co-cultures with allogeneic mDC-FasL, whereas a strong proliferative T-cell response could be observed in co-cultures with enhanced green fluorescent protein-transduced mDC. Inhibition of T-cell proliferation was related to the transduction efficiency, and the numbers of mDC-FasL present in co-cultures. In addition, proliferation of pre-activated alloreactive CD4(+) and CD8(+) T cells could be almost completely inhibited in secondary co-cultures using mDC-FasL as stimulatory cells, which was the result of induction of apoptosis in the majority of preactivated T cells. The specific deletion of alloreactive T cells by mDC-FasL was confirmed by an unaffected proliferative response of surviving T cells towards allogeneic 'third-party' peripheral blood mononuclear cells in a third stimulation, or upon unspecific stimulation with anti-CD3/CD28 beads. The results of this study demonstrate that allospecifically activated T cells are efficiently eliminated by mDC-FasL, supporting further investigations to apply FasL-expressing 'killer-DC' as a novel strategy for the treatment of allograft rejection.
© 2011 The Authors. Immunology © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21342185      PMCID: PMC3088973          DOI: 10.1111/j.1365-2567.2011.03417.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  42 in total

Review 1.  Death receptor signaling and its function in the immune system.

Authors:  Stefanie C Fas; Benedikt Fritzsching; Elisabeth Suri-Payer; Peter H Krammer
Journal:  Curr Dir Autoimmun       Date:  2006

Review 2.  Development of dendritic-cell lineages.

Authors:  Li Wu; Yong-Jun Liu
Journal:  Immunity       Date:  2007-06       Impact factor: 31.745

Review 3.  Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells.

Authors:  Kazunori Onoé; Yoshiki Yanagawa; Keita Minami; Norifumi Iijima; Kazuya Iwabuchi
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

Review 4.  Dendritic cells: nature and classification.

Authors:  Katsuaki Sato; Shigeharu Fujita
Journal:  Allergol Int       Date:  2007-08-01       Impact factor: 5.836

Review 5.  Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells.

Authors:  Nathalie Cools; Peter Ponsaerts; Viggo F I Van Tendeloo; Zwi N Berneman
Journal:  J Leukoc Biol       Date:  2007-08-21       Impact factor: 4.962

6.  Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections.

Authors:  Masahiro Kusuhara; Hiroyuki Matsue
Journal:  Exp Dermatol       Date:  2005-04       Impact factor: 3.960

7.  Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity.

Authors:  G Strauss; W Osen; I Knape; E-M Jacobsen; S M Müller; K-M Debatin
Journal:  Cell Death Differ       Date:  2006-08-11       Impact factor: 15.828

Review 8.  Taking dendritic cells into medicine.

Authors:  Ralph M Steinman; Jacques Banchereau
Journal:  Nature       Date:  2007-09-27       Impact factor: 49.962

9.  Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.

Authors:  Christian Schütz; Martin Fleck; Andreas Mackensen; Alessia Zoso; Dagmar Halbritter; Jonathan P Schneck; Mathias Oelke
Journal:  Blood       Date:  2007-12-20       Impact factor: 22.113

Review 10.  Life and death in peripheral T cells.

Authors:  Peter H Krammer; Rüdiger Arnold; Inna N Lavrik
Journal:  Nat Rev Immunol       Date:  2007-07       Impact factor: 53.106

View more
  4 in total

1.  Killer artificial antigen presenting cells (KaAPC) for efficient in vitro depletion of human antigen-specific T cells.

Authors:  Christian Schütz; Martin Fleck; Jonathan P Schneck; Mathias Oelke
Journal:  J Vis Exp       Date:  2014-08-11       Impact factor: 1.355

2.  A biodegradable killer microparticle to selectively deplete antigen-specific T cells in vitro and in vivo.

Authors:  Wei Wang; Kun Fang; Miao-Chen Li; Di Chang; Khawar Ali Shahzad; Tao Xu; Lei Zhang; Ning Gu; Chuan-Lai Shen
Journal:  Oncotarget       Date:  2016-03-15

3.  An Antigen-Presenting and Apoptosis-Inducing Polymer Microparticle Prolongs Alloskin Graft Survival by Selectively and Markedly Depleting Alloreactive CD8+ T Cells.

Authors:  Wei Wang; Khawar Ali Shahzad; Miaochen Li; Aifeng Zhang; Lei Zhang; Tao Xu; Xin Wan; Chuanlai Shen
Journal:  Front Immunol       Date:  2017-06-09       Impact factor: 7.561

Review 4.  Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective.

Authors:  Anja Ten Brinke; Marc Martinez-Llordella; Nathalie Cools; Catharien M U Hilkens; S Marieke van Ham; Birgit Sawitzki; Edward K Geissler; Giovanna Lombardi; Piotr Trzonkowski; Eva Martinez-Caceres
Journal:  Front Immunol       Date:  2019-02-22       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.